Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634932 | 0.88 | GFER (0.53) | GFERKDM4EGAAIDO1HDAC8 | |
| SCHEMBL639362 | 0.79 | GFER (0.61) | GFERKDM4EGAAIDO1HDAC8 | |
| SCHEMBL3341447 | 0.79 | KDM4E (0.61) | GFERKDM4EGAAIDO1HDAC8 | |
| SCHEMBL3344186 | 0.79 | KDM4E (0.61) | GFERKDM4EGAAIDO1HDAC8 | |
| SCHEMBL15567968 | 0.78 | KDM4E (0.56) | GFERKDM4EGAAIDO1HDAC8 | |
| SCHEMBL3343038 | 0.77 | GFER (0.64) | GFERKDM4EGAAHDAC8ALDH1A1 | |
| SCHEMBL258911 | 0.77 | GAA (1.00) | GFERKDM4EGAAIDO1HDAC8 | |
| Hydrochloric Acid SCHEMBL3342876 | 0.75 | GAA (0.96) | GFERKDM4EGAAIDO1HDAC8 | |
| SCHEMBL638114 | 0.75 | GFER (0.56) | GFERKDM4EGAAIDO1HDAC8 | |
| SCHEMBL640481 | 0.75 | GFER (0.56) | GFERKDM4EGAAIDO1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160401-A1 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH | GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE | 2010-06-24 | — | — | US | claimed |
| EP-2885306-B1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2016-06-01 | — | — | EP | disclosed |
| EP-2885306-A1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-20150157739-A1 | Imidazo[2,1]thiazol-3-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014026881-A1 | IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-20 | — | — | WO | disclosed |
| US-20100160401-A1 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH | GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE | 2010-06-24 | — | — | US | disclosed |
| EP-2164486-A2 | USE OF 4-PHENYL-IMIDAZOLE-2-THIONES AS TYROSINASE INHIBITORS FOR PREPARING PHARMACEUTICAL OR COSMETIC COMPOSITIONS FOR TREATING OR PREVENTING PIGMENT DISORDERS | Galderma Research & Development (FR) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008152330-A2 | USE OF 4-PHENYL-IMIDAZOLE-2-THIONES AS TYROSINASE INHIBITORS FOR PREPARING PHARMACEUTICAL OR COSMETIC COMPOSITIONS FOR TREATING OR PREVENTING PIGMENT DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160401-A1 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH | TYR, TH, PAH | GFER 2509/4885KDM4E 1018/4885GAA 58/4885 |
| US-20150157739-A1 | Imidazo[2,1]thiazol-3-one derivatives | MAPT, SNCA, PARK7 | GFER 3102/4885KDM4E 4876/4885GAA 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.